Healthcare Costs

Private equity giant Lightyear Capital backs benefits platform Corestream, a strategic move signaling tech's pivotal role in the future of employee retention.

Vertex's new CF drug, ALYFTREK, clears a major hurdle in Canada, promising a once-daily treatment and new hope for patients previously left behind.

A new video series from Anthem and USA TODAY aims to educate consumers. But is it a public service or a sophisticated marketing strategy to cut costs?

The nation's largest physician-owned insurer pulls back the curtain on plastic surgery malpractice, revealing that clinical judgment, not just technical skill, is a top driver of costly claims.

As America prepares for its 250th anniversary, a new film highlights a silent crisis. 63 million unpaid caregivers form a $600B shadow economy facing collapse.

Cerezen, a non-invasive device shown to reverse cognitive decline, has EU approval but remains in FDA limbo, raising questions about US patient access.

A St. John's innovator just won a key national award for easing hospital overcrowding. Is their model the scalable solution Canada has been waiting for?

Millions of older Americans can now access the popular weight-loss drug Wegovy for a $50 copay, a temporary move that could reshape healthcare policy and the pharma market.

The FDA approved Orca Bio's revolutionary cell therapy, promising better outcomes for cancer patients. But the real test lies beyond the science.

The FDA's approval of a potent new triglyceride drug comes with a staggering price tag, forcing a showdown with an established, affordable therapy.

As population growth strains West Central Florida, a new state budget infusion for BayCare reveals a targeted strategy to bolster critical healthcare infrastructure.

Sound Accountable Care's rebrand is more than a name change. It's a strategic pivot backed by $114M in Medicare savings, aiming to capture the entire senior care market.

New data shows pet parents are using telehealth for immediate advice, reducing ER visits and empowering them to make smarter, faster care decisions.

Health Canada's approval of a generic Wegovy promises to slash costs and expand access, shifting the landscape for patients and the healthcare system.

After a fierce campaign reversed drastic cuts to Florida's HIV drug program, thousands can breathe again. But a new cap and missing aid reveal a fragile victory.

The BCDA launches a new charitable foundation, a strategic pivot to secure the 'Save a Smile' program and tackle BC's growing oral health disparities.

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

A $20M funding round for Upside signals a market shift. Payers and employers are now betting on AI and human care to solve housing instability for profit.

A new CMS program offers seniors blockbuster obesity drugs for $50. But this temporary fix raises profound questions about cost, access, and our healthcare future.

With over 1,200 positions cut, Ontario's nurses protest a system they say is failing patients. Is this a fiscal necessity or a strategic shift toward privatization?